Inscripta  

Boulder,  CO 
United States
https://www.inscripta.com/
  • Booth: 1427

Inscripta has developed the world’s first benchtop platform for scalable Digital Genome Engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, reagents, and software, offers a fully automated workflow that enables multiplexed, trackable editing of cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease free for research purposes, the company is enabling scientists to realize a new era of biological discovery. Inscripta is headquartered in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego.

Join us for lunch on Wed, Oct. 16th from 12:45-2:00 pm at Hilton Americas, Houston, Lanier Ballroom DE, Level 4 to hear Deanna Church present: Digital Genome Engineering: Yeast as a Gateway to Human Biology. https://www2.inscripta.com/ASHG2019

Brands: Onyx


 Videos

Meet Your New Genome Engineering Tool

 Press Releases

  • Inscripta Launches the World’s First Benchtop Platform for Digital Genome Engineering

    The Onyx™ platform enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow

    Boulder, CO – October 1, 2019 – Inscripta, Inc., today announced the launch of the Onyx™ Digital Genome Engineering platform, the world’s first fully automated benchtop instrument for genome-scale engineering. The CRISPR-mediated, massively parallel platform — which includes software, consumables, instrument, and assays — enables researchers to engineer microbial libraries containing the full breadth and scope of possible edit types, in their own labs. This new genome engineering platform will offer immediate and significant benefits that will support bio-industrial materials development and manufacturing, genome discovery, healthcare, and sustainability.  

    The company is launching the platform today at the SynBioBeta 2019 conference in San Francisco. Those interested in watching the live presentation by Inscripta CEO Kevin Ness, PhD, can join the webinar at the following link at 10:00 a.m. Pacific Time: https://zoom.us/j/639508467.

    Prior to commercial release, Inscripta has been collaborating with global key opinion leaders in academia and industry through an early access program. A selection of the scientists involved in the program highlighted the various advantages the Inscripta platform provides for their particular applications. 

    James J. Collins, PhD, Termeer Professor of Medical Engineering and Science at MIT, said: “Inscripta’s platform has afforded us the opportunity to explore the genetic dependencies of antibiotic function in unprecedented detail. The knowledge garnered through this technology has significant potential to lead to the development of novel therapeutics against our most difficult antibiotic-resistant pathogens.”

    Markus Herrgard, PhD, Director of Data Science and Automation at the Novo Nordisk Foundation Center for Biosustainability at Technical University of Denmark, added: “The Inscripta platform is a perfect match to the ambitious goals for the Novo Nordisk Foundation Center for Biosustainability to enable the transition from a fossil fuel-based economy to a bio-based economy. The platform allows us to rapidly and cost-effectively engineer large numbers of genetic changes into microbial cell factories. This will significantly accelerate our progress in creating new cell factories for sustainable production of chemicals.”

    Another early access user, Chris Savile, PhD, Vice President of Commercial Operations at Willow Biosciences, commented: “Inscripta’s technology enables us to generate and screen large libraries of precisely edited strains on a scale never seen before. Our heterologous pathway and strain engineering efforts benefit greatly from the reduced cycle times and increased learnings offered by the platform. These unparalleled capabilities will be used to accelerate our microbial R&D programs and shorten time to market.”

    “At Inscripta, we believe that biology has unlimited potential to positively change the world. We are inspired by the ambitious experiments our early access collaborators have run with our platform and are proud to see the impact our technology is already having on the synthetic biology field,” said Dr. Ness. “CRISPR-based gene editing technology has the potential to transform our ability to precisely engineer genomes, but it has not yet fully delivered on this promise due to significant limitations. The Onyx platform overcomes these limitations and will give all scientists the power to design, engineer, evaluate, and track results of powerful genome engineering experiments in their own lab. We believe that this technology will transform the capabilities of genome writing and enable researchers to focus their efforts on testing multiple biological hypotheses in parallel without having to outsource their experiments or spend precious time and resources on the laborious task of optimizing complex gene editing methods.”

    About Inscripta

    Inscripta is developing the world's first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal is to empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7™ CRISPR nuclease free for research and development purposes, the company enables scientists to realize a new era of biological discovery. Headquartered in Boulder, Colo, with offices in Pleasanton, Calif., and San Diego, Inscripta is backed by leading investors including Venrock, Foresite, Mérieux Développement, Paladin Capital Group, MLS Capital, and NanoDimension. For more information, visit www.inscripta.com

    Contact:

    Nicole Litchfield

    Bioscribe, Inc.

    415-793-6468

    nicole@bioscribe.com

    Or

    Michelle Linn

    Bioscribe, Inc.

    774-696-3803

    michelle@bioscribe.com


 Products

  • Onyx™ Digital Genome Engineering Platform
    The fully automated Onyx Digital Genome Engineering Platform platform is a complete benchtop solution, consisting of design and analysis software, custom consumables, and a fully automated instrument for genome engineering....

  • Inscripta introduces the fully automated Onyx Digital Genome Engineering Platform. Current gene-editing techniques are insufficient to realize the full potential of genome engineering; they lack the required scale, performance, and access. With the Inscripta Onyx platform, you can build the most extensive libraries, engineered with the widest variety of edit types—all with the push of a single button. The Onyx platform is a complete benchtop solution, consisting of design and analysis software, custom consumables, and a fully automated instrument. No expert gene-editing knowledge is required. Bring genome engineering at scale to your lab, making the previously impossible a reality. Only with the Onyx Digital Genome Engineering Platform.

  • Onyx™ S. cerevisiae Genome Engineering Kit
    Kit for use with strains related to yeast S. cerevisiae strain S288c for creation of libraries with one edit per cell....

  • Access the richness of the entire genetic landscape

    Build libraries with diverse edit types including insertions, deletions and swaps in coding and non-coding regions across Saccharomyces cerevisiae genomes. Explore a wide variety of phenotypes with edited libraries, either in pools of cells or in isolated cells.

    • Massively parallel single edits
      • 100 – 10,000 edits
    • Greater than 30% expected edit efficiency
      • 15% — 75% depending on design library parameters
    • Greater than 70% library coverage for designs at all plexities
    • Massively parallel, precision edit payload:
      • Insertions: up to ~60 bp
      • Deletions: up to ~75 bp
      • Swaps: up to ~60 bp
  • Onyx™ S. cerevisiae Custom Strain Assessment Kit
    In addition to specific strains supported by Inscripta, the Onyx™ platform may allow you to edit other strains of S. cerevisiae....

  • Access the richness of the entire genetic landscape

    Build libraries with diverse edit types including insertions, deletions and swaps in coding and non-coding regions across the Saccharomyces cerevisiae genomes. Explore a wide variety of phenotypes with edited libraries, either in pools of cells or in isolated cells.

  • Onyx™ E. coli Genome Engineering Kit
    Genome engineering kit for use with strains related to E. coli K‑12 strain MG1655 and B strain BL21....

  • Access the richness of the entire genetic landscape

    Build libraries with diverse edit types including insertions, deletions and swaps in coding and non-coding regions across Escherichia coli genomes. Explore a wide variety of phenotypes with edited libraries, either in pools of cells or in isolated cells.

    • Massively parallel single edits
      • 100 – 10,000 edits
    • Greater than 30% expected edit efficiency
      • 15% — 75% depending on design library parameters
    • Greater than 70% library coverage for designs at all plexities
    • Massively parallel, precision edit payload:
      • Insertions: up to ~60 bp
      • Deletions: up to ~75 bp
      • Swaps: up to ~60 bp

Questions or Need Assistance?

Email exhibits@ashg.org

Technical support: Support

For more tips, visit the FAQ.

Featured Products
View All

Want your product featured here? Click to upgrade your online exhibitor listing.